IGLV: A Promising Drug Target for IPMS1P20 (G96610)

Target Name: BMS1P20

NCBI ID: G96610

BMS1P20

Other Name(s): IGLV | IGLV1 | BMS1 pseudogene 20 | IGL

IGLV: A Promising Drug Target for IPMS1P20

The remission-phase thrombocytopenia (IPMS1P20) is an autoimmune disease primarily characterized by a decrease in platelets, leading to bleeding and bruising. Currently, IGLV (Inotuzumab ozogamicin) is considered a promising drug target for the treatment of IPMS1P20. This article will introduce IGLV as a drug target, as well as its role and mechanism in the treatment of IPMS1P20.

Mechanism of action of IGLV

IGLV is a monoclonal antibody that inhibits platelet aggregation by binding to CD11b molecules on the surface of platelets, thereby improving platelet survival rate. IGLV can significantly increase the patient's platelet count and reduce the patient's bleeding risk.

Clinical application of IGLV

Currently, IGLV has proven its effectiveness in multiple clinical trials. In a clinical trial of IPMS1P20 patients, patients' platelet counts significantly improved and the incidence of bleeding events was significantly reduced after receiving IGLV treatment.

Biological targets of IGLV

The biological targets of IGLV mainly include CD11b molecules on the surface of platelets and survival-inhibitory factors within platelets. CD11b molecule is an important platelet surface marker and a key molecule for platelet aggregation. IGLV inhibits platelet aggregation by binding to CD11b molecules, thereby improving platelet survival rate.

Survival-inhibitory factor is an important platelet regulatory molecule that can inhibit platelet aggregation and release, thereby controlling platelet function. IGLV controls platelet function by binding to survival-inhibitory factors and inhibiting platelet aggregation and release.

Summarize

As a new drug target, IGLV has significant therapeutic effect in the treatment of IPMS1P20. With the deepening of research, IGLV, as a potential drug target, will be more widely used in the treatment of IPMS1P20.

Protein Name: BMS1 Pseudogene 20

The "BMS1P20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMS1P20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets